Overall, these findings suggest that moderating obesity-driven inflammatory pathways, particularly IL-6 signaling and NLRP3 inflammasome activation, may reduce clonal expansion and mitigate the metabolic sequelae associated with CHIP. This evidence concerns the gene IL6 and obesity due to melanocortin 4 receptor deficiency.